TURKOVAC

TURKOVAC is a COVID-19 vaccine candidate developed by the Scientific and Technological Research Council of Turkey (TÜBİTAK) and the Erciyes University. It is an inactivated vaccine, which means it uses a non-infectious version of the coronavirus to stimulate an immune response in the body.

Development and Testing

The development of TURKOVAC began in early 2020, shortly after the COVID-19 pandemic began. The vaccine is produced by inactivating the SARS-CoV-2 virus with chemicals, rendering it non-infectious but still capable of stimulating an immune response.

Phase 1 and 2 clinical trials for TURKOVAC began in late 2020, with results indicating that the vaccine is safe and produces a strong immune response. Phase 3 trials began in mid-2021, involving thousands of participants across multiple countries.

Efficacy

While the final results of the Phase 3 trials are not yet available, preliminary data suggests that TURKOVAC is effective at preventing COVID-19. The vaccine has been shown to stimulate the production of antibodies and T cells, both of which are crucial for fighting off the virus.

Distribution and Usage

Pending the results of the Phase 3 trials and regulatory approval, TURKOVAC is expected to be distributed both within Turkey and internationally. The vaccine can be stored at standard refrigerator temperatures, making it easier to distribute than some other COVID-19 vaccines.

See Also

• COVID-19 vaccination
• COVID-19 vaccine
• Inactivated vaccine
• COVID-19 pandemic